about
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenasesIDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patientsIsolation and identification of a distinct side population cancer cells in the human epidermal squamous cancer cell line A431.Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature.Biology, genetics and imaging of glial cell tumoursA pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.A simplified approach for the molecular classification of glioblastomasHow molecular testing can help (and hurt) in the workup of gliomas.Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosisPrognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.What do we know about IDH1/2 mutations so far, and how do we use it?Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in gliomaPrognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.Prognostic markers in gliomas.Predictive and prognostic factors for gliomas.Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).IDH mutations in human gliomaRelationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.[Personalized therapy for gliomas].A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas.
P2860
Q24632807-8C307017-B00F-47B2-99E2-E44B70AD64E3Q33597773-BDE813A5-70F9-42F8-9998-17F2EEC52E83Q33794969-964AC921-7102-4975-91A2-8801559EAA33Q33831823-D0A9F636-E1C0-4150-83CB-8BD91A9B11E5Q33984130-2FF51083-195F-4DEE-ADEE-A17CB663A2F9Q34203979-4F4A8995-862E-422B-8720-4A3D92C689FCQ34239738-FD177B5F-577F-4440-94E9-B98591BB9714Q34308674-992E3605-FFAA-473E-A84D-38AC98276840Q34429149-2B149D76-5502-48D9-8922-3CB02EA72BF2Q35770275-B2D5DC63-4907-49B1-BFA8-CBA7EA1FD5D8Q36107360-3F84F5CC-7520-4D7D-BD81-5B2C294189D1Q36713512-65054560-F0F8-43B2-8997-CC709C12E521Q36788229-0B3FC025-6DA4-4E77-9737-C4E0A8FCDF15Q36809370-66D8E6BB-2A75-41EC-9E05-AE46986810B4Q37496863-C0B0648D-CE64-483F-A5A2-61DAAECDD1B0Q37750781-01231F0F-B0A1-4418-8392-9D6044EC43BAQ37873473-D2394297-93C5-402F-8BD3-5B125B4CBAD2Q38022242-620B9E29-C8D7-46B7-8F61-8FDC729336D8Q38022856-BCDE9658-4FC2-4A12-91A8-E0AF77A65F66Q46082218-2DFBA205-87A7-4C08-9038-EACA43F6F576Q48161996-3632A3BD-DCC5-4E93-BD43-0BBD8BB910DBQ55460034-A912A0E3-119B-4C54-8A18-62230A4F1142Q55461252-29A9D48C-A1D0-4638-AFFA-2DEF312E82AA
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Diagnostic and prognostic markers in gliomas.
@en
Diagnostic and prognostic markers in gliomas.
@nl
type
label
Diagnostic and prognostic markers in gliomas.
@en
Diagnostic and prognostic markers in gliomas.
@nl
prefLabel
Diagnostic and prognostic markers in gliomas.
@en
Diagnostic and prognostic markers in gliomas.
@nl
P1476
Diagnostic and prognostic markers in gliomas.
@en
P2093
Ahmed Idbaih
Soufiane El Hallani
P304
P356
10.1097/CCO.0B013E32833065A7
P577
2009-11-01T00:00:00Z